期刊文献+

负载肿瘤干细胞膜微粒抗原的半相合异基因树突细胞-细胞因子诱导的杀伤细胞治疗T淋巴母细胞淋巴瘤一例并文献复习

Semi-allogeneic dendritic cells-cytokine-induced killer cells loaded with tumor stem cell membrane-based microparticles antigen in treatment of T-lymphoblastic lymphoma:report of one case and review of literature
原文传递
导出
摘要 目的观察负载肿瘤干细胞膜微粒抗原的半相合异基因树突细胞-细胞因子诱导的杀伤细胞(DC-CIK)治疗T淋巴母细胞淋巴瘤(T-LBL)的疗效。方法回顾性分析攀枝花学院附属医院收治的1例应用负载膜微粒抗原的半相合异基因DC-CIK治疗的T-LBL患儿的临床资料,并复习相关文献。结果该患儿经颈部淋巴结活组织检查确诊为T-LBL,入院时血常规无异常,影像学示浅表及深部淋巴结肿大,骨髓淋巴母细胞0.230,脑脊液未见异常,诊断为T-LBLⅣ期。予改良BFM-90方案化疗及规范鞘内注射治疗,骨髓完全缓解后给予4个疗程共12次输注负载肿瘤干细胞膜微粒的半相合异基因DC-CIK。细胞治疗11个月后复查骨髓淋巴母细胞为0.095。至截稿前随访患儿仍正常学习、生活。结论T-LBL是一种高侵袭性的淋巴瘤,预后差。规范化疗联合负载肿瘤干细胞膜微粒的异基因DC-CIK可作为T-LBL治疗的一种新选择。
作者 徐薇 高泽莉 魏立 杨小芸 张菊 Xu Wei;Gao Zeli;Wei Li;Yang Xiaoyun;Zhang Ju(Department of Hematology,Affiliated Hospital of Panzhihua University,Panzhihua 617000,China;Department of Pharmacy,Air Force Medical University,Xi'an 710032,China)
出处 《白血病.淋巴瘤》 CAS 2020年第12期747-749,共3页 Journal of Leukemia & Lymphoma
基金 四川省攀枝花市科技计划(2017TX-1)。
  • 相关文献

参考文献4

二级参考文献37

  • 1王琦,任秀宝,蒋敬庭.肺癌免疫细胞治疗临床转化的研究进展[J].中国肿瘤生物治疗杂志,2015,22(3):375-380. 被引量:11
  • 2王娜,赵勇.LMO2与T细胞白血病[J].细胞生物学杂志,2005,27(3):253-256. 被引量:4
  • 3Sun J C, Pan K, Chen M S, et al. Dendritic cells-mediated CTLs targeting hepatocellular carcinoma stem cells[ J]. Canc- er Biol Ther, 2010, 10(4) : 368 -375.
  • 4Laport G G, Sheehan K, Baker J, et al. Adoptive immnno- therapy with cytokine-induced killer cells for patients with re- lapsed hematologic malignancies after allogeneic hematopoietic cell transplantation[J]. Biol Blood Marrow Transplant, 2011, 17(11) : 1679 -1687. DOI: 10. 1016/j. bbmt. 2011. 05. 012.
  • 5Kroger N, Zabelina T, van-Biezen A, et al. Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis [ J ]. Haematologica, 2011, 96 (2) : 291 - 297. DOI: 10.3324/haematol. 2010. 031229.
  • 6Lankester A C, Bierings M B, van-Wering E R, et al. Pre- emptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation [ J ]. Leukemia, 2010, 24(8) : 1462 -1469. DOI: 10. 1038/1eu. 2010. 133.
  • 7Deol A, Lum L G. Role of donor lymphocyte infusions in re- lapsed hematological malignancies after stem cell transplanta- tion revisited[J]. Cancer Treat Rev, 2010, 36(7) : 528 - 538. DOI : 10. 1016/j. ctrv. 2010.03. 004.
  • 8Yang B, Wang J, Cai L L, et al. Treatment of muhiple soli- tary plasmacytomas with cytokine-induced killer ceils [ J ]. Cy- totherapy, 2014, 16(2) : 278 -284. DOI: 10. 1016/j. jcyt. 2013.11. 001.
  • 9Kuci S, Rettinger E, Voss B, et al. Efficient lysis of rhabdomyosarcoma ceils by cytokine-induced killer cells: implica- tions for adoptive immunotherapy after allogeneic stem cell transplantation[ J ]. Haematologica, 2010, 95 (9) : 1579 - 1586. DOI: 10. 3324/haematol. 2009.019885.
  • 10Linn Y C, Niam M, Chu S, et al. The anti-tumour activity of allogeneic cytokine-indnced killer cells in patients who relapse after allogeneic transplant for haematological malignancies [J]. Bone Marrow Transplant, 2012, 47 (7): 957 -966. DOI: 10. 1038/bmt. 2011. 202.

共引文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部